Vascular Biogenics (Vascular Biogenics) Total Equity : $19.24 Mil (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Total Equity?

Vascular Biogenics's total equity for the quarter that ended in Jun. 2023 was $19.24 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Vascular Biogenics Total Equity Historical Data

The historical data trend for Vascular Biogenics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Total Equity Chart

Vascular Biogenics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Equity

Get a 7-Day Free Trial

53.09

36.02

30.92

52.18

22.45

Vascular Biogenics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Equity	Get a 7-Day Free Trial															34.37	25.31	22.45	19.90	19.24

Vascular Biogenics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Vascular Biogenics's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2022 )	-	Total Liabilities(Q: Dec. 2022 )
	=	29.659	-	7.208
	=	22.45

Vascular Biogenics's Total Equity for the quarter that ended in Jun. 2023 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2023 )	-	Total Liabilities(Q: Jun. 2023 )
	=	24.646	-	5.409
	=	19.24

Vascular Biogenics Total Equity Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vascular Biogenics (Vascular Biogenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 HaSatat Street, Modi’in, ISR, 7178106

Website

https://www.vblrx.com

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Executives

Builders Vc Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim	10 percent owner	C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner	officer: Chief Scientific Officer	320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi	director	320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock	director, officer: Chief Executive Officer	320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen	director	320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p.	10 percent owner	2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p.	10 percent owner	C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142